Evaluation of a synthetic wound dressing capable of releasing silver sulfadiazine.
A silver sulfadiazine-impregnated poly-L-leucine wound dressing, AgSD-medicated wound dressing, was evaluated for antibacterial capacity against Pseudomonas aeruginosa and cytotoxicity to human fibroblasts and human epidermal keratinocytes. This wound dressing contained 0.4 mg AgSD/cm2. Antibacterial capacity was examined on experimentally infected wound surfaces (3.4 x 10(4) P. aeruginosa organisms/gm) on the dorsum of mice. The AgSD-medicated wound dressing showed effective bacterial control. Cytotoxicity was examined on a monolayer of cells formed in culture dishes. Cellular damage was reduced by the controlled release of AgSD from the hydrophobic poly-L-leucine sponge matrix of the AgSD-medicated wound dressing. Cytotoxicity of the AgSD-medicated wound dressing was much lower than that of 1% AgSD cream.
Kuroyanagi
Y
Y
Department of Biomedical Engineering, School of Medicine, Kitasato University, Sagamihara, Japan.
Kim
E
E
Shioya
N
N
D000818:Animals; D001424:Bacterial Infections / Q000517:prevention & control; D001672:Biocompatible Materials / Q000627:therapeutic use; D002056:Burns / Q000150:complications; D002452:Cell Count / Q000187:drug effects; D002478:Cells, Cultured; D020099:Coated Materials, Biocompatible; D003692:Delayed-Action Preparations; D005347:Fibroblasts / Q000187:drug effects; D006801:Humans; D051379:Mice; D009779:Occlusive Dressings; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012837:Silver Sulfadiazine / Q000633:toxicity*; D012867:Skin / Q000166:cytology
C042816:Biobrane; D001672:Biocompatible Materials; D020099:Coated Materials, Biocompatible; D003692:Delayed-Action Preparations; D012837:Silver Sulfadiazine